Larita M Condon, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 253 W Sixth St, Minster, OH 45865 Phone: 419-501-2165 Fax: 419-501-2166 |
Heather M Frey, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 50 E 7th St, Minster, OH 45865 Phone: 419-614-4128 |
Jennifer Will Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 24 N Hamilton St, Minster, OH 45865 Phone: 419-628-2396 |
Mrs. Margaret M Harrod, MED-CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 253 W Sixth St, Minster, OH 45865 Phone: 419-501-2165 Fax: 419-501-2166 |
News Archive
The Ontario Association of Medical Laboratories is pleased to announce its 2010 Small Grants Program to support non-proprietary research projects to improve the efficiency or effectiveness of the delivery of laboratory services. Previously funded projects have included research into new testing methodologies, information systems and improvements to operational systems.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
Envision announced today that Second Sight Medical Products, Inc., a San Fernando Valley, Calif.-based medical device manufacturer, and Janet Sunness, M.D., Medical Director of Richard E. Hoover Low Vision Rehabilitation Services at Greater Baltimore Medical Center in Towson, Md., were named the 2014 recipients, respectively, of the Envision Oculus Award and Envision Award in Low Vision Research, two prestigious honors acknowledging substantial contributions to furthering research and facilitating collaborative efforts toward addressing low vision and the conditions that cause it.
Some people call it "the dark time," the period between when a person is diagnosed with Parkinson's disease and when treatment with medication begins.
› Verified 4 days ago